All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-08-16T14:39:51.000Z

Supplemental BLA for Adcetris® (brentuximab vedotin) in CTCL granted Priority Review by the FDA

Aug 16, 2017
Share:

Bookmark this article

On 16th August 2017, the U.S. Food and Drug Administration (FDA) accepted the Supplemental Biologics License Application (sBLA) submitted by Seattle Genetics, Inc., for Adcetris® (brentuximab vedotin) in the treatment of patients with Cutaneous T-Cell Lymphoma (CTCL). Furthermore, the FDA has granted Priority Review of this application with a target action date of 16th December 2017.

The sBLA is based on data from the phase III ALCANZA trial (NCT01578499), which compared brentuximab vedotin to methotrexate or bexarotene in relapsed/refractory CD30+ CTCL patients. The results of the trial were published in The Lancet in June of this year, which the Lymphoma Hub reported on; read more here. Also, while at this year’s ICML conference, we interviewed Professor Miles Prince from the Peter MacCallum Cancer Center, Melbourne, Australia, on the ALCANZA trial; watch it here.

  • Brentuximab vedotin demonstrated a statistically significant improvement in the rate of Objective Response lasting at least four months (ORR4) compared to the control arm as assessed by an independent review facility
  • ORR4 assessed by Global Response Score was 56.3% with brentuximab vedotin versus5% with control treatment (P < 0.0001)
  • CR, PFS, and reduction in the burden of symptoms during treatment (Skindex-29) were all highly statistically significant in favor of brentuximab vedotin
  • The safety profile associated with brentuximab vedotin was largely consistent with the present prescribing information; the most frequently observed AEs of any grade included anemia, peripheral sensory neuropathy, nausea, diarrhea, fatigue, and neutropenia

Additional data from two investigator-sponsored phase II studies were also included in the sBLA. Currently, Adcetris® is not approved by the FDA or the European Medicines Agency (EMA) for CTCL.

  1. Digital Journal. FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma. 2017 Aug 16. http://www.digitaljournal.com/pr/3451106. [Accessed 2017 Aug 16].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox